Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

4.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.8K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

2.3K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.6K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dengue hospitalizations in Brazil: Forecasting with climatic and physicians' digital search data under real-world reporting delays.

PLOS digital health·2026
Same author

Hospitalisations in Brazil: an ecological time series analysis of the impact of medical decision support data as an exogenous variable.

BMC public health·2025
Same author

Comparative Efficacy and Safety of Benzodiazepines in the Treatment of Patients with Generalized Anxiety Disorder: A Systematic Review and Network Meta-Analysis.

Psychotherapy and psychosomatics·2025
Same author

Evaluating ChatGPT-4 for the Interpretation of Images from Several Diagnostic Techniques in Gastroenterology.

Journal of clinical medicine·2025
Same author

Effects of dopamine β-hydroxylase inhibition in pressure overload-induced right ventricular failure.

Pulmonary circulation·2024
Same author

Discovery of a Potent, Selective, and Blood-Brain Barrier Permeable Non-nitrocatechol Inhibitor of Catechol-<i>O</i>-methyltransferase.

Journal of medicinal chemistry·2024

Related Experiment Video

Updated: Apr 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase

Nuno Miguel Pires1, Bruno Igreja1, Eduardo Moura1

  • 1Department of Research & Development, BIAL-Portela & Ca, S.A., S. Mamede do Coronado, Portugal.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|April 10, 2015
PubMed
Summary

Renal denervation provided temporary blood pressure reduction in rats, while inhibiting dopamine β-hydroxylase (DβH) with etamicastat offered sustained blood pressure control by reducing noradrenaline levels.

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K
Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

11.2K

Related Experiment Videos

Last Updated: Apr 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K
Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
11:08

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

11.2K

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Nephrology

Background:

  • Sympathetic nervous system overactivity contributes to arterial hypertension.
  • Renal denervation (RDN) is a new treatment for drug-resistant hypertension.
  • Inhibiting dopamine β-hydroxylase (DβH) offers an alternative to modulate sympathetic nerve function.

Purpose of the Study:

  • To compare the effects of RDN and DβH inhibition on blood pressure and sympathetic nerve activity.
  • To evaluate the long-term efficacy of etamicastat, a DβH inhibitor, versus RDN in hypertensive rats.

Main Methods:

  • Spontaneously hypertensive rats (SHR) underwent RDN or received etamicastat (30 mg/kg/day).
  • Blood pressure, renal function, and noradrenaline (NA) levels were monitored over 28 days.
  • Water balance, renal function, and urinary electrolytes were assessed.

Main Results:

  • Both RDN and etamicastat did not affect renal function.
  • RDN temporarily reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP).
  • Etamicastat significantly decreased SBP and DBP throughout the study period.
  • NA levels decreased in renal tissue for both groups; only etamicastat reduced left ventricle NA.

Conclusions:

  • RDN provides transient blood pressure reduction.
  • Sustained sympathetic inhibition via DβH inhibition with etamicastat leads to prolonged blood pressure lowering.
  • Etamicastat presents a promising therapeutic strategy for sustained hypertension management.